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Abstract 
Exogenous hydrogen sulfide (H2S) leads to down-regulation of inflammatory responses and 
provides myocardial protection during acute ischemia/reperfusion injury; however its role 
during chronic heart failure (CHF) due to myocardial infarction (MI) is yet to be unveiled. We 
previously reported that H2S inhibits antiangiogenic factors such, as endostatin and angio-
statin, but a little is known about its effect on parstatin (a fragment of proteinase-activated 
receptor-1, PAR-1). We hypothesize that H2S inhibits parstatin formation and promotes 
VEGF activation, thus promoting angiogenesis and significantly limiting the extent of MI injury. 
To verify this hypothesis MI was created in 12 week-old male mice by ligation of left anterior 
descending artery (LAD). Sham surgery was performed except LAD ligation. After the surgery 
mice were treated with sodium hydrogen sulfide (30 μmol/l NaHS, a donor for H2S, in 
drinking water) for 4 weeks. The LV tissue was analyzed for VEGF, flk-1 and flt-1, endostatin, 
angiostatin and parstatin. The expression of VEGF, flk-1 and flt-1 were significantly increased 
in treated mice while the level of endostatin, angiostatin and parstatin were decreased 
compared to in untreated mice. The echocardiography in mice treated with H2S showed the 
improvement of heart function compared to in untreated mice. The X-ray and Doppler blood 
flow measurements showed enhancement of cardiac-angiogenesis in mice treated with H2S. 
This observed cytoprotection was associated with an inhibition of anti-angiogenic proteins 
and stimulation of angiogenic factors. We established that administration of H2S at the time of 
MI ameliorated infarct size and preserved LV function during development of MI in mice. 
These results suggest that H2S is cytoprotective and angioprotective during evolution of MI. 
Key words: Hydrogen sulfide, VEGF, flk-1, flt-1, endostatin, angiostatin, parstatin Myocardial in-
farction 
Introduction 
Cardiovascular  disease  (CVD)  is  the  leading 
cause  of  death  for  human  population.  Myocardial 
infarction  (MI),  one  of  the  most  devastating  conse-
quences of CVD, leads to an upregulation of various 
growth factors [1, 2] and tissue remodeling. Vascular 
endothelial  growth  factor  (VEGF),  the  most  promi-
nent member of a family of growth factors is strong-
ly associated with angiogenic stimuli in different pa-
thologies  [3-8],  thus  most  likely  plays  a  role  in  left 
ventricular (LV)  remodeling  after  MI.  Recent  obser-
vations  showed  that  VEGF  expression  is  also  sub-
stantially  increased  in  chronically  ischemic  myocar-
dium [9, 10] as well as it is increased instantly after 
myocardial ischemia [11]. VEGF is thought to stimu-
late  endothelial  cell  proliferation  and  to  increase 
permeability  by  binding  with  high-affinity  to  two 
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receptors  expressed  predominantly  on  endothelial 
cells such as the tyrosine kinase receptor - flk-1 [12] 
and the fms-like tyrosine kinase - flt-1[6]. Flt-1 may 
mediate  vascular  organization,  and  flk-1  mediates 
endothelial differentiation and proliferation [12, 13]. 
These receptors interact and modify biological effects 
of VEGF either positively or negatively, depending on 
the specific vascular bed, the experimental condition, 
and  disease  state  [14].  Interestingly,  impairment  of 
endogenous  angiogenesis  in  several  pathologic  and 
physiologic  conditions,  such  as  diabetes,  hypercho-
lesterolemia, and aging, has been associated with re-
duced production of VEGF [15-17]. In previous stud-
ies we demonstrated that MI causes hyperhomocys-
teinemia (HHcy) that is promoted by downregulation 
of  5-Methyltetrahydrofolate  (5-MTHFR),  cystathi-
onine-β-synthase  (CBS)  and  cystathionine-γ–lyase 
(CSE)  [18].  Inhibition  of  angiogenesis  recently  has 
been described as a new deleterious effect of HHcy 
[19, 20] H2S is known to be produced in the vascula-
ture by CSE and to mediate smooth muscle relaxation 
and subsequent vasodilatation [21]. Previous studies 
suggest that the heart is one of the major sources of 
the  H2S  [22].  Exogenous  H2S  provides  myocardial 
protection  during  myocardial  ischemia/reperfusion 
by  opening K+ATP channels in  cardiomyocytes  and 
down-regulating of inflammatory responses [23]. Re-
cent  studies  demonstrated  that  H2S  de-
creased apoptosis, level of inflammation, and size of 
ischemia in the setting of myocardial ischemia reper-
fusion [24]. Although previous studies reported that 
endostatin  and  angiostatin  expression  and  activity 
were  significantly  elevated  in  hypertrophied  hearts 
[25],  only  a  few  studies  have  examined  the  role  of 
parstatin  during  heart  failure [26-29]  in 
post-myocardial  remodeling  and  dysfunction.  We 
previously  showed  that  MI  causes  upregulation  of 
MMP-9, that increases levels of anti-angiogenic fac-
tors and contributes LV heart failure [18, 30]. In this 
study,  we  tested  whether  exogenous  H2S  reduced 
heart injury after stimulation of VEGF and inhibition 
of anti-angiogenic factors in MI mice.  
Materials and Methods 
Animals:  Ten  weeks  old  wild  type  (WT) 
C57BL6/J  male  mice  were  obtained  from  Jackson 
Laboratories  (Bar  Harbor,  ME.,)  and  housed  in  the 
animal care facility at the University of Louisville with 
access to standard chow and tap water. At the age of 
12 weeks with an approximate weight of 25-29 grams, 
animals underwent MI surgery or sham surgery. Af-
ter  surgery  mice  were  divided  in  two  groups:  one 
group was given plain tap water and another were 
given NaHS (H2S donor; Sigma), which in aqueous 
solution  releases  H2S,  in  drinking  water  for  4  wk. 
Although  there  are  differences  in  the  physiological 
range of H2S and some reports say that it is much 
lower than the micromolar level, a 30 μmol/l concen-
tration was supplemented to keep the plasma H2S in 
the physiological range, which is widely variable from 
5  to  300  μmol/l.  Diffusion  of  H2S  into  room  air  is 
minimal since its density is 18% higher than that of 
air.  Furthermore,  the  drinking  water  was  changed 
daily with fresh NaHS solution to provide adequate 
levels of H2S to the mice. To estimate daily intake of 
NaHS,  previous  studies  from  our  lab  reported  that 
there was no difference in the consumption of water 
among the treated and untreated groups and also that 
there  was  an  increase  in  plasma  H2S  concentration 
with exogenous supplementation. It was reported that 
oxidation of H2S due to air occurs. This yields slightly 
yellow colored water. Since we changed the drinking 
solution daily and did not see changes in water col-
oring (it was always yellow to the same extent) we 
presumed that the content of NaHS in drinking water 
was changing significantly [25]. To supplement H2S 
continuously water supply was changed every 24 h. 
At  the  end  of  the  study,  animals  were  euthanized, 
deeply  anesthetized  with  thribromoethanol  (con-
firmed  by  tail/toe  pinch).  For  heart  excision,  mice 
were injected with 20 % KCl solution (0.2 ml/100 g 
body weight that causes heart arrest in diastole). Then 
hearts were excised. This was consistent with a vet-
erinarian view of euthanasia. All experiments using 
mice were approved by and performed according to 
the  Guidelines  for  the  care  and  Use  of  laboratory 
Animals  in  University  of  Louisville,  which  strictly 
conformed to the Guide for the Care and Use of La-
boratory Animals published by the US National In-
stitutes of Health (NIH Publication No. 85-23, revised 
1996). 
Mouse  model  of  Myocardial  Infarction:  Ani-
mals  were  anesthetized  with  sodium  pentobarbital 
(70mg/kg),  intubated  and  ventilated  with  Harvard 
mini  ventilator.  Body  temperature  was  maintained 
with a heating pad (TR 200, Fine Science Tools, Foster 
City, CA). A left thoracotomy was performed via the 
fourth  intercostal  space  and  the  lungs  retracted  to 
expose the heart. After opening the pericardium, left 
anterior descending artery (LAD) was ligated with an 
8-0 silk suture near its origin between the pulmonary 
outflow tract and the edge of the atrium. Ligation was 
deemed successful when the anterior wall of the left 
ventricle turned pale. The lungs were inflated by in-
creasing  positive  end-expiratory  pressure  and  the 
thoracotomy side closed in layers. Animals were kept 
on a heating pad until they recovered. Another group 
of mice underwent a sham ligation surgery. They had Int. J. Biol. Sci. 2012, 8 
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a similar surgical procedure done without tightening 
the  suture  around  the  LAD.  The  lungs  were 
re-expanded and chest was closed. The animals were 
removed from the ventilator and allowed to recover 
on a heating pad. After surgery animals allowed to 
recover in the lab and monitored until their full re-
covery. Then animals were transferred to the animal 
care  unit.  Animals  were  checked  daily  for  signs  of 
pain  or  distress  (hunch  back,  restricted  movement, 
etc.)  and  carprofen  at  5mg/kg  subcutaneous  was 
given after surgery once a day during 48 hours. Rec-
ords of observations and procedures were kept in the 
lab.  
Echocardiography: Before and 4 weeks after the 
surgery,  two-dimensional  (2-D)  echocardiography 
was  performed  on  mice  using  a  Hewlett-Packard 
Sonos  5500  ultrasonography  with  a  15-MHz  trans-
ducer. The mice were sedated with fresh made 2,2,2 
tribromethanol ((100 mg/kg IP)TBE, Sigma T48 402; 
240 mg/kg of Bd. wt.), and the chest was shaved. The 
mice  were  placed  in  a  custom-made  cradle  on  a 
heated platform in the supine or the left lateral decu-
bitus  position  to  facilitate  echocardiography.  For 
quantification of LV dimensions and wall thickness. 
LV  short-  and  long-axis  loops  and  LV  2-D  im-
age-guided M-mode traces at the  level that yielded 
the  largest  diastolic  dimension  were  digitally  rec-
orded. LV dimensions (LVDs) at diastole and systole 
(LVDd and LVDs, respectively) were measured from 
five cycles and averaged. Fractional shortening (FS) 
was  calculated  as  [(LVDd−LVDs)/LVDd]  ￗ100%. 
Fractional  area  change  (FAC)  was  derived  from 
end-diastolic  and  end-systolic  areas  of  short-axis 
loops. According to the single-plane Simpson method, 
LV  volumes  at  end-diastole  (EDV)  and  end-systole 
(ESV)  were  derived  from  long-axis  loops.  Ejection 
fraction  (EF)  was  calculated  as  [(EDV−ESV)/EDV] 
×100%.  
Western Blot analysis: Changes in protein con-
tent of CBS, CSE, endostatin, and angiostatin, induced 
by  MI  were  assessed  by  Western  blot  analyses  ac-
cording to the method described earlier [16]. Briefly, 
frozen  heart  tissue  washed  twice  with  ice-cold  PBS 
and lysed with ice-cold RIPA buffer (containing 5 mM 
of ethylenediamine-tetraacetic acid), which was sup-
plemented  with  phenylmethylsulfonyl  fluoride  (1 
mM) and protease inhibitor cocktail (1 ml/ml of lysis 
buffer). Protein content of the lysate was determined 
using the Bicinchronic Acid protein assay kit (Pierce, 
Rockford, IL). Equal amounts of protein (30 mg) were 
resolved on 12% SDS-PAGE and transferred onto a 
polyvinylidene difluoride membrane as described [31, 
32].  The  blots  were  incubated  with  monoclonal  an-
ti-mouse  CBS  (1:1500  dilution,  C#  H00000875-M01), 
and  anti-mouse  CSE  (1:1500  dilution,  C# 
H00001491-M02) antibodies (Novus Biologicals), anti 
–mouse Endostatin (1:1500), and anti-rat Angiostatin 
(1:1500) for 1 h at room temperature. After incubation, 
the proteins on blots were detected as described [31]. 
Membranes were stripped and re-probed for -actin 
as  a  loading  control.  The  blots  were  analyzed  with 
Gel-Pro Analyzer software (Media Cybernetics, Silver 
Spring,  MD)  as  described  earlier  [33].  The  protein 
expression  intensity  was  assessed  by  the  integrated 
optical density (IOD) of the area of the band in the 
lane profile. To account for possible differences in the 
protein load, the measurements presented are the IOD 
of each band under study (protein of interest) divided 
by the IOD of the respective -actin band. 
Histology  and  confocal  microscopy:  Hearts 
were collected from experimental animals and thor-
oughly washed in PBS. For fixation, hearts were per-
fused  with  4%  paraformaldehyde  and  preserved  in 
Peel-A-Way  disposable  plastic  tissue  embedding 
molds  (Polysciens  Inc,  Washington,  PA)  filled  with 
tissue  freezing  media  (triangle  Biomedical  Sciences, 
Durham, NC) and stored at -700 C until analysis. Tis-
sue  sections  (5  µm  in  thickness)  were  made  using 
Leica CM 1850 Cryocut (Bannockburn, IL, USA). Sec-
tions  were  placed  on  Super  frost  plus  glass  slides, 
air-dried,  and  processed  for  histological  and  Im-
munohistochemistry (IHC) staining. 
Histology:  Masson’s  trichrome  staining  was 
performed on frozen tissue sections using a Masson’s 
trichrome kit (Richard-Allan Scintific, Kalamazoo, MI) 
according  to  the  manufacturer’s  recommendations. 
The heart muscle and vascular smooth muscle were 
stained a pink while the collagen was blue. The level 
of subcellular matrix collagen was assessed by meas-
uring the optical density of blue color. For quantita-
tion we choose the same distance from septal wall. For 
example  we  choose  2-3  mm  from  apex-septal  wall. 
Because of that in MI we have whole part of scar and 
in MI+H2S we have border-zone. Ischemic zone itself 
in MI+H2S is very small compare to MI.  
Immunohistochemistry: Immunohistochemistry 
was  performed  on  frozen  tissue  sections  using  a 
standard  IHC  protocol.  Primary  antibodies  applied 
overnight  included  anti-endostatin,  anti-angiostatin, 
anti-parstatin, anti-Hcy, and anti- MTHFR antibodies 
(all  from  Abcam,  Cambridge,  MA).  Secondary  anti-
bodies labeled with Alexa Fluor 488 and Texas Red 
(Invitrogen,  Carlsbad,  CA)  were  applied  for  immu-
nodetection of these proteins. Stained slides were an-
alyzed for fluorescence using a laser scanning confo-
cal microscope (Olympus FluoView-1000, objective 60 
xs) set at the appropriate filter settings. The total flu-
orescence (green or red) intensity in 5 random fields Int. J. Biol. Sci. 2012, 8 
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(for  each  experimental  sample)  was  measured  with 
image analysis software (Image-Pro Plus, Media Cy-
bernetics). Fluorescence intensity values for each ex-
perimental  group  were  averaged  and  presented  as 
fluorescent intensity units (FIU). 
Coronary angiography: We used barium sulfate 
for post mortem imaging of mice vasculature [30]. The 
size of barium particles range from 1-100 µm whereas 
most of the mice micro vasculature is less than 30 µm. 
Moreover  barium  sulfate  is  insoluble  in  water.  To 
overcome this problem, we dissolved barium sulfate 
in acidic pH buffer and the mixture was used for in-
travascular infusion. All images were taken with Ko-
dak 4000 MM image station. Dissected animals were 
placed in the X-ray chamber and angiogram images 
were  captured  with  high  penetrative  phosphorous 
screen by 31 KVP X-ray exposure for 3 minutes using 
high  resolution  phosphorous  screen  and  aperture 
settings of approximately 4.0, f-stop-12 and zoom of 
40 mm. 
RNA  extraction:  RNA  from  LV  was  extracted 
using Trizol method. The purity of RNA was estimate 
by NanoDrop (ND-1000) and only highly pure quality 
RNA  (260/280–2.00  and  260/230–2.0)  was  used  for 
RT-PCR. 
Reverse  transcription-polymerase  chain  reac-
tion: The RT-PCR was performed using Promega kit, 
following  their  protocol  (Promega  Corporation, 
Madison,  WI,  USA,)[34].  The  RT-PCR  amplification 
program  was  [95 °C–0.50 min,  55 °C–1.00 min, 
72 °C–1.00 min] × 34, 72 °C–5.00 min, 4 °C-∞. 
The primers for RT-PCR were: 
VEGF- F- 5’ GGA CCC TGG CTT TAG TGC 3’ 
R- 5’CCG GCT TGG CGA TTT AG 3’ 
Flk-1- F- 5’ GGT GCC CGC TCT TTG 3’ 
R- 5’TGT CTC AGT GGG GAT TGC 3’ 
Flt-1- F- 5’ CCT GGC TA CCC GAT TCC 3’ 
R- 5’ TCC CGC TTT GTT GAT GGC 3’ 
In  vivo  blood  flow  measurement:  Mice  were 
anesthetized with Pentobarbital (70mg/kg) were in-
tubated,  thoracic  cavity  was  opened  and  heart  was 
exposed for blood flow measurement. Body temper-
ature  was  maintained  between  37-  39  ºC  using  a 
heating pad. The part for measurement was chosen to 
be 1cm2. The probe was always placed 1cm below the 
ligation or (in Sham animals) the place where the li-
gation would have been if we performed it. Carprofen 
(5mg/kg  subcutaneous)  was  administered  after  in-
duction  of  anesthesia.  Blood  flow  on  the  heart  was 
measured by using LASER DOPPLER IMAGING flow 
meter. 
Statistical analysis: Values are reported as mean 
  SEM.  Differences  between  groups  were  tested  by 
two-way ANOVA. If ANOVA indicated a significant 
difference  (P  <  0.05),  Tukey’s  multiple  comparison 
test  was  used  to  compare  group  means  and  were 
considered significant if P < 0.05. 
Results 
To  determine  cardiac  function,  echocardiog-
raphy measurements were obtained immediately be-
fore and 4 weeks after the surgery. Results are shown 
in Table 1. All variables were similar in animals of all 
groups immediately before the surgery and remained 
unaltered  in  the  Sham  group  throughout  the  study 
period (Table 1). Supplementation with H2S did not 
alter  fraction  shortening  (FS),  LVDd,  and  LVDs  in 
Sham mice (Table 1). Induction of MI resulted in de-
crease of FS and increase of LVDd and LVDs (Table 1). 
Treatment with H2S decreased dilation of heart and 
improved FS, LVDd and LVDs in mice with MI (Table 
1).  
 
Table 1: Comparison of LV chamber dimension and frac-
tion shortening (FS) in sham-operated (Sham), myocardial 
infarction-induced (MI), sham-operated and treated with 
H2S (Sham+H2S), and myocardial infarction-induced and 
treated with H2S (MI+H2S) mice. 
Experimental groups  Sham  Sham+H2S  MI  MI+ H2S 
FS,%  64±0.4  65±0.8  28±0.4*  47±0.3*# 
LVDd, mm  2.17±0.5  2.16±0.3  3.2±0.5*  2.85±0.5*# 
LVDs, mm  0.87±0.2  0.98±0.5  2.15±0.4*  1.6±0.9*# 
Presented results are calculated from the following equation 
[(LVDd−LVDs)/LVDd] ￗ100%. 
* P < 0.05 vs. Sham and Sham+H2S, # P<0.05 vs. MI; n=9 for all 
groups. 
 
 
To determine the levels of fibrosis, histological 
analysis of collagen was performed on the LV. The 
intensity  of  trichrome  blue  stain  demonstrated  de-
velopment  of  significant  fibrosis  on  the  LV  in  MI 
hearts  as  compared  to  Sham  (Figure1  A  and  B). 
Treatment with H2S mitigated the formation of fibro-
sis on the left ventricle in MI+H2S group (Figure1 A 
and B). 
 Role of H2S in Hcy / MTHFR axis: The confocal 
image  analyses  of  Hcy  and  MTHFR  indicated  that 
induction  of  MI  increased  HCY  expression  and  de-
creased MTHFR expression in heart tissue compared 
to Sham (Figure 2 A and B). Supplementation with 
H2S restored this effect in MI+H2S group (Figure 2). 
Treatment  of  Sham  mice  with  H2S  (Sham+H2S)  did 
not  change  expression  of  Hcy  and  MTHFR  in  their 
hearts compared to those in Sham group (Figure 2 A 
and B).  Int. J. Biol. Sci. 2012, 8 
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Figure 1. Heart wall anatomical changes in sham-operated (Sham), myocardial infarction-induced (MI), sham-operated and treated with 
H2S (Sham+H2S), and myocardial infarction-induced and treated with H2S (MI+H2S) animals. A: Examples of cross-sectional view of the 
left ventricular (LV) walls of Sham, Sham+H2S, MI and MI+H2S hearts. Note: No visible necrosis was found in the LV wall of hearts from 
Sham and Sham+H2S mice. B: Collagen-associated (blue) intensity changes in hearts from experimental animals. C: Changes in expression 
of parstatin protein contents, by immunohistochemistry analysis, in hearts from Sham, myocardial infarction-induced (MI), sham-operated 
and treated with H2S (Sham+ H2S), and myocardial infarction-induced and treated with H2S (MI+ H2S) mice. D Bar graph of changes in 
Sham, myocardial infarction-induced (MI), sham-operated and treated with H2S (Sham+H2S), and myocardial infarction-induced and 
treated with H2S (MI+H2S) mice heart tissue. The micrographs were taken under the identical set of conditions for all groups. * P < 0.05 
vs. Sham, Sham+H2S, and MI+H2S. # p<0.05 vs. MI. n=6 for all group. 
 
 
 
Role of H2S in expression of CBS and CSE: In-
duction  of  MI  significantly  decreases  expression  of 
CBS, and CSE in mice heart (Figure 2 C and D). In-
terestingly  supplementation  with  H2S  restored  ex-
pression of CSE in hearts from mice with MI (Figure 2 
C and D). Treatment of H2S did not change expression 
of CBS in mice with MI. Supplementation with H2S 
did not affect expression of CBS and CSE in Sham+ 
H2S mice compared to those in Sham group (Figure 2 
C and D). 
Angiogenic role of H2S: A total RNA Expression 
of VEGF and its receptors: flk-1 and flt-1 were quanti-
fied by PCR  of RNAs extracted from the entire LV 
(including both infarcted and non-infarcted regions at 
various time intervals after coronary ligation). To fa-
cilitate comparison of absolute changes in expression 
between VEGF and its receptors, baseline expression 
of each gene in the normal LV was arbitrarily set at 
100, and results from animals with infarctions were 
scaled  in  proportion.  Coronary  ligation  induced  a 
profound increase in VEGF expression over the time 
course of the study.  
 Int. J. Biol. Sci. 2012, 8 
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Figure 2. A. Changes in expression of MTHFR (green) and HCY (red) protein contents, by immunohistochemistry analysis, in hearts 
from Sham, myocardial infarction-induced (MI), sham-operated and treated with H2S (Sham+ H2S), and myocardial infarction-induced and 
treated with H2S (MI+ H2S) mice. B. Bar graph of changes in integrated optical density (IOD) in expression of MTHFR and Hcy in Sham, 
MI, Sham+H2S, and MI+ H2S mice heart tissues. The micrographs were taken under the identical set of conditions for all groups. C and 
D. Changes in expression of CSE and CBS proteins contents, by Western blot analysis, in hearts from Sham, myocardial infarction-induced 
(MI), sham-operated and treated with H2S (Sham+ H2S), and myocardial infarction-induced and treated with H2S (MI+ H2S) mice. Examples 
of Western blot images of the proteins studied and contents of β-actin in the respective samples and results of the Western blot analysis, 
relative protein expression is reported as ratio of integrated optical density (IOD) of each band to the IOD of the respective β-actin band. 
* P < 0.05 vs. Sham, Sham+H2S, and MI+H2S. # p<0.05 vs. MI. n=6 for all group. 
 
 
VEGF expression was increased as early as 1 d in 
MI heart (Figure 3B). It was dramatically (more than 
twice) increased in MI+H2S mice. Treatment with H2S 
did not have an effect in sham group. One week after 
MI, expression of VEGF in H2S-treated MI mice was 
similar to that in untreated MI mice, but it was still 
greater than in sham group (Figure 3B). Four weeks 
after MI expression of VEGF decreased to the level 
found in sham group (Figure 3B). Expression of flk-1 
in MI mice treated with H2S after 1 day of surgery was 
greatly  increased  compared  to  Sham  operated  mice 
(Figure 3C). The expression of flk-1 was significantly 
increased  in  MI  mice  without  H2S  treatment  com-
pared to sham group, but it was less than in MI mice 
treated with H2S (Figure 3C). Treatment with H2S did 
not have an effect on sham group (Figure 3C). Flk-1 
expression in MI mice treated with H2S decreased to 
the  level  of  MI  mice  without  H2S  treatment  after  1 
week of surgery, but it was still greater than in sham 
group (Figure 3C). From 1 to 4 weeks after surgery, 
there  were  no  changes  in  expression  of  flk-1  in  MI 
mice treated with H2S (Figure 3C). In mice without 
H2S  treatment,  expression  of  flk-1  decreased  to  the 
level of sham group 4 weeks after surgery (Figure 3C). 
During the first day all MI groups experienced a sharp 
increase  in  Flt-1  expression  (Figure  3D).  After  one Int. J. Biol. Sci. 2012, 8 
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week  of  surgery  H2S-treated  MI  mice  continued  to 
increase expression in flt-1 at a reduced rate (Figure 
3D). Untreated MI mice showed a decrease in expres-
sion of flt-1, but that was still greater than in sham 
group (Figure 3D). The expression of flt-1 was same 
for all the groups after 4 weeks of surgery (Figure 3D). 
Anti anti-angiogenic role of H2S: The confocal 
image  analysis  indicated  that  induction  of  MI  in-
creased endostatin, angiostatin, and parstatin expres-
sion in heart tissue compared to those in Sham (Figure 
1C, 1D, and 4). Supplementation with H2S decreased 
this effect in MI+H2S group (Figure 1C, 1D, and 4), 
although they were still greater than in Sham animals. 
Treatment  of  Sham  mice  with  H2S  (Sham+H2S)  did 
not change expression of endostatin, angiostatin, and 
parstatin  in  heart  compared  to  those  in  untreated 
Sham group (Figure 1C, 1D, and 4).  
Collateralization:  The  X-ray  vascular  density 
data showed increase in angiogenic vessels at 4 weeks 
after  MI  in  H2S-treated  mice.  Capillary  rarefaction 
was  observed  at  4th  weeks  post  MI  without  the 
treatment with H2S (Figure 5). 
Blood  flow  measurement:  To  corroborate  the 
vascular density data with the blood flow we meas-
ured blood flow by Laser Doppler. Induction of MI 
significantly impaired blood flow in MI mice (Figure 
6). Supplementation with H2S increased blood flow in 
mice with MI (Figure 6). Supplementation with H2S 
did not affect blood flow  in Sham+  H2S mice com-
pared to those in Sham group (Figure 6).  
 
 
Figure 3. Changes in expression of VEGF, flk-1 and flt-1 RNA contents, by RT-PCR analysis, in hearts from Sham, myocardial infarc-
tion-induced (MI), sham-operated and treated with H2S (Sham+ H2S), and myocardial infarction-induced and treated with H2S (MI+ H2S) 
mice. A: Examples of PCR images of the RNA studied and contents of GAPDH in the respective samples. B: Results of the VEGF RT-PCR 
analysis. Relative RNA expression is reported as ratio of integrated optical density (IOD) of each band to the IOD of the respective 
GAPDH. C: Results of the flk-1 RT-PCR analysis. Relative RNA expression is reported as ratio of integrated optical density (IOD) of each 
band to the IOD of the respective GAPDH, D: Results of the flt-1 RT-PCR analysis. Relative RNA expression is reported as ratio of 
integrated optical density (IOD) of each band to the IOD of the respective GAPDH; * P < 0.05 vs. Sham, Sham+ H2S, and MI+ H2S. # P < 
0.05 vs. MI. n=7 for all groups. Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
437 
 
Figure 4. A. Changes in expression of endostatin (green) and angiostatin (red) protein contents, by immunohistochemistry analysis, in 
hearts  from  Sham,  myocardial  infarction-induced  (MI),  sham-operated and  treated with  H2S  (Sham+  H2S),  and  myocardial  infarc-
tion-induced and treated with H2S (MI+ H2S) mice. B. Bar graph of changes in integrated optical density (IOD) in expression of endostatin 
and angiostatin for all groups. C and D. Examples of Western blot images of the endostatin and angiostatin proteins studied and contents 
of β-actin in the respective samples. Relative protein expression is reported as ratio of integrated optical density (IOD) of each band to the 
IOD of the respective β-actin band. * P < 0.05 vs. Sham, Sham+H2S, and MI+H2S. # P<0.05 vs. MI. n=6 for all group. 
 
 
Figure  5.  Barium-contrast 
X-ray images of the hearts from 
sham,  myocardial  infarc-
tion-induced  (MI), 
sham-operated and treated with 
H2S (Sham+H2S), and myocardial 
infarction-induced  and  treated 
with H2S (MI+H2S) mice: Note: 
There is an increase in collateral 
vessels in the MI heart after H2S 
treatment  compared  to  MI. 
A.X-ray  images  from  experi-
mental groups. B. Bar graph of 
changes  in  integrated  optical 
density  (IOD)  in  expression  of 
Barium.  C.  analyzing  x-ray  pic-
tures in image-pro system.  
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Figure 6. Heart blood flow A: Examples of blood flow of the left ventricular (LV) walls of Sham, Sham+H2S, MI and MI+H2S hearts. Note: 
No visible changes were found in the LV wall’s blood flow of hearts from Sham and Sham+H2S mice. B: Bar graph of changes in Flux (AU) 
in MI, Sham+H2S, and MI+ H2S mice heart tissues. C. Example of the blood flow measurement on the heart * P < 0.05 vs. sham group, # 
P < 0.05 vs. MI; n=6 for all groups. 
 
Discussion 
The principal findings of this study were that an 
exogenous administration of NaHS, a H2S donor at 
the  time  of  MI  limits  the  extent  of  MI  in  an in  vi-
vo mouse  model.  A  dose–response  study  revealed 
that H2S displayed a biphasic reduction in infarct size 
as has previously been reported by Johansen et al [35, 
36]. Importantly, the decrease in infarct size translated 
into reduced LV dilatation and improved LV function 
as measured by echocardiography.  
H2S  is  generated  from  L-cysteine  in  reactions 
catalyzed by CBS or CSE. CSE is primarily responsible 
for  most  of  the  H2S  production  in  the  vasculature 
[37-39]. We show that exogenous H2S increased level 
of CSE in MI heart and limited the extent of injury. 
Our data supported the hypothesis that the in-
duction of CSE in heart tissue activates endogenous 
angiogenic  agent  VEGF  via  inhibition  of  an-
ti-angiogenic factors like angiostatin, endostatin and 
parstatin.  This  promotes  new  vessels  in  heart  and 
reduced  infarct  size  in  MI  mice.  Further  our  study 
demonstrated  that  VEGF  expression  was 
up-regulated in H2S treated mice with MI. VEGF re-
ceptors  flk-1  and  flt-1  were  induced  maximally  in 
MI+H2S mice. Our results confirmed results of pre-
vious studies [40] and suggested that treatment with 
H2S after MI has beneficial effects on the heart. This 
may be related to the expression of angiogenic cyto-
kines  and  their  receptors,  such  as  VEGF,  flk-1  and 
flt-1.  VEGF  is  a  key  growth  factor  in  physiological 
angiogenesis and induces angiogenesis in myocardial 
ischemia  and  MI  [2,  41-44].  Many  studies  have  fo-
cused  on  the  expression  of  angiogenic  factors  after 
infarction, especially VEGF and its receptors. VEGF 
was a strong mitogen, highly specific to endothelial Int. J. Biol. Sci. 2012, 8 
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cells.  Its  specific  receptors  include  flt-1  and  flk-1, 
which  are  receptor  tyrosine  kinases  and  predomi-
nantly  expressed  in  endothelial  cells  [45].  In  our 
studies,  both  temporal  and  spatial  changes  in  flk-1 
expression  were  observed  after  MI.  Whereas  flk-1 
RNA was up-regulated at day 1 and down-regulated 
at 4th week after induction of MI. Expression of flt-1 
was up-regulated continuously during first week and 
down-regulated after 4 weeks of MI induction. It was 
found that flt-1 played a role in the later stages of an-
giogenesis  [45].  In  contrast  to  flt-1,  Flk-1  was  ex-
pressed earlier. Flk-1 plays a major role in angiogene-
sis and endothelial cell survival [46]. 
The findings of this study indicate that myocar-
dial levels of the antiangiogenic proteins angiostatin, 
endostatin and parstatin are increased in MI mice. The 
myocardial levels of angiostatin, endostatin and par-
statin have a strong negative correlation to coronary 
collateralization  in  MI  mice,  which  mitigates  its  re-
duction of endostatin, angiostatin and parstatin and is 
positively correlated with more collateralization in MI 
mice  treated  with  H2S.  Endostatin,  a  powerful  en-
dogenous inhibitor of angiogenesis, has been shown 
to reduce blood flow locally [47]. Endostatin, angio-
statin and parstatin inhibits endothelial cell prolifera-
tion,  migration  and  tube  formation in  vitro  [47-49], 
and  possesses  potent  inhibitory  effects  on  tumor 
growth in  vivo  [50].  The  inhibitory  effects  of  an-
ti-angiogenic  factors  on  the  expression  of  VEGF  in 
tumor cells and on vascular permeability have been 
reported [50, 51]. 
In conclusion, we have shown that exogenously 
given H2S at the time of MI limits the extent of infarc-
tion. This protection is accompanied by a decrease in 
myocardial  anti-angiogenic  factors,  such  as  en-
dostatin, angiostatin and parstatin, and a preservation 
of growth factors such as VEGF, flk-1 and flt-1. These 
results suggest that H2S therapy may be a promising 
candidate for the treatment of MI. 
Limitation:  To  confirm  the  theory  exposure  of 
CSE in heart tissue activates endogenous angiogenic 
agent VEGF via inhibition of anti-angiogennic factors, 
the  investigation  using  anti  VEGF  antibody  and/or 
CSE knockout mice is necessary. These investigations 
are in progress.  
To  quantify  the  presumed  augmented  angio-
genesis, it may appear that there is lack of clarity be-
tween ischaemic zone and infarct size, and the lack of 
CD31 data from the IHC study. We substantiated this 
by measuring VEGF gene expression this may lead to 
increase in VEGF protein levels. The message stabili-
zation is a common way of increasing VEGF protein 
there are some reports of the opposite trend. 
The  timing  of  infarct  size  reduction  with  H2S 
treatment and improved LV function is related to an-
giogenesis is supported by the evidences, in part by 
blood flow measurement. 
The CD31 data and barium contrast X-ray anal-
ysis  only  reveal  the  macrovascular  expansion,  and 
does not provide any direct evidence for angiogenesis 
(capillary  growth).  Indeed,  Fig  6  is  consistent  with 
collateral dilatation. 
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